Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07490067 · ClinicalTrials.gov registry record · Phase 4
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
A Phase 4 study, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT07490067 is a Phase 4 study that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 100 participants.
The verdict
NCT07490067, a Phase 4 study, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: * HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score.
Interventions
- DRUG Metoprolol Succinate
- DEVICE Beta-Blocker Polygenic Score
- DEVICE Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07490067
The ClinicalTrials.gov registry entry for NCT07490067 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metoprolol Succinate is the first listed.
NCT07490067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07490067 about?
NCT07490067 is a clinical study titled "Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score". The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will b...
What is the current status of trial NCT07490067?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07490067?
The interventions under investigation include: Metoprolol Succinate (DRUG), Beta-Blocker Polygenic Score (DEVICE), Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx) (DEVICE).
Who is sponsoring clinical trial NCT07490067?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.